In today’s ACT Brief, we examine how sponsors are reassessing new engagement technologies to avoid increasing site burden, ...

Danish pharma major Novo Nordisk has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide and semaglutide) injection, to be used ...

The stock is currently trading near 304 Danish kroner in Copenhagen and around $47 for its American Depositary Receipts (ADRs). This level remains far below its 52-week high of nearly $110 per ADR.

Dow Jones Top Company Headlines at 11 PM ET: OpenAI's New Fundraising Round Could Value Startup at as Much as $830 Billion | Wells ... OpenAI's New Fundraising Round Could Value Startup at as Much as ...

Health-care companies ticked up as traders rotated back into higher risk sectors. Eli Lilly shares rose after the maker of weight-loss drugs filed for U.S. Food and Drug Administration approval of a ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.

Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the ...

Dow Jones Top Financial Services Headlines at 11 AM ET: Novo Nordisk Files For FDA Approval of Obesity Drug CagriSema | Deerpath ... Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, ...

Novo Nordisk’s NDA filing for CagriSema positions the first fixed-dose amylin–GLP-1 combination as a potential ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

The company formally lodged its New Drug Application (NDA) with the U.S. Food and Drug Administration on Thursday. CagriSema is viewed as the potential successor to the blockbuster drug Wegovy. It ...